Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease
Status: | Recruiting |
---|---|
Conditions: | Peripheral Vascular Disease, Peripheral Vascular Disease, Cardiology, Cardiology, Cardiology, Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/8/2018 |
Start Date: | October 31, 2018 |
End Date: | May 30, 2019 |
Contact: | Pam DiCamillo, LVN, CRCC |
Email: | PDiCamillo@ECR-Inc.com |
Phone: | 903-352-2714 |
Artimes Pro Low Profile 1.00mm and 1.25mm Dilatation Catheters for Pre-Dilatation of Stenosis and Occlusion in Patients With Symptomatic Ischemic Heart Disease
This is a prospective, non-randomized, open label, multi-center study including 60 patients
with symptomatic ischemic heart disease with 70%-100% coronary artery stenoses and occlusions
enrolled and treated in this investigational device study.
with symptomatic ischemic heart disease with 70%-100% coronary artery stenoses and occlusions
enrolled and treated in this investigational device study.
Patients who require initial pre-dilatation using the study device, and then undergo
definitive therapy using additional PTCA catheters and stents, according to standard of care
will be enrolled in this study.
A maximum of 60 subjects with native coronary artery lesions or occlusions will be treated
using the Artimes pro Balloon Dilatation Catheters in a 3:1 ratio using the 1.0mm and 1.25mm
dilatation catheters for pre-dilatation and will complete the study within the U.S. This
equals 45 patients treated using the 1.0mm dilatation catheter, and 15 patients treated with
the 1.25mm dilatation catheter for a total of 60 subjects enrolled and treated.
definitive therapy using additional PTCA catheters and stents, according to standard of care
will be enrolled in this study.
A maximum of 60 subjects with native coronary artery lesions or occlusions will be treated
using the Artimes pro Balloon Dilatation Catheters in a 3:1 ratio using the 1.0mm and 1.25mm
dilatation catheters for pre-dilatation and will complete the study within the U.S. This
equals 45 patients treated using the 1.0mm dilatation catheter, and 15 patients treated with
the 1.25mm dilatation catheter for a total of 60 subjects enrolled and treated.
Inclusion Criteria:
- At least 18 years of age;
- Willing and able to provide informed consent;
- Willing and able to meet all study requirements;
- Patients with symptomatic ischemic heart disease due to stenotic lesions or occlusions
in coronary arteries that are amenable to percutaneous coronary interventions;
- Patients who tolerate DAPT
Exclusion Criteria:
- A known hypersensitivity or contraindication to aspirin, heparin, or bivalirudin,
anti-platelet medications, or sensitivity to contrast media, which cannot be
adequately pre-medicated;
- LVEF < 30%;
- Evidence of an acute myocardial infarction within 72 hours of the intended index
procedure;
- Planned treatment of unprotected left main disease;
- History of cerebral vascular accident (CVA) within 6 months prior to consideration for
this study;
- Transient ischemic attack (TIA) within 6 months prior to consideration for this study;
- Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months prior to
consideration for this study;
- History of bleeding diathesis or coagulopathy;
- Refuses blood transfusions;
- Any general contraindication to revascularization procedures;
- Pregnant or lactating;
- In the judgement of the investigator, patient is not a suitable candidate for this
study.
We found this trial at
2
sites
Indianapolis, Indiana 46290
Principal Investigator: Michael W Ball, MD
Phone: 317-583-6303
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Jasvindar Singh, MD
Phone: 314-747-1612
Click here to add this to my saved trials